140 related articles for article (PubMed ID: 3119776)
21. Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis.
Brooke MH; Florence JM; Heller SL; Kaiser KK; Phillips D; Gruber A; Babcock D; Miller JP
Neurology; 1986 Feb; 36(2):146-51. PubMed ID: 3080694
[TBL] [Abstract][Full Text] [Related]
22. A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis.
Caroscio JT; Cohen JA; Zawodniak J; Takai V; Shapiro A; Blaustein S; Mulvihill MN; Loucas SP; Gudesblatt M; Rube D
Neurology; 1986 Feb; 36(2):141-5. PubMed ID: 3080693
[TBL] [Abstract][Full Text] [Related]
23. The long loop reflex in spinocerebellar degeneration and motor neuron disease--its changes with TRH therapy.
Touge T; Takeuchi H; Yamada A; Miki H; Nishioka M
Electromyogr Clin Neurophysiol; 1990; 30(3):131-40. PubMed ID: 2112456
[TBL] [Abstract][Full Text] [Related]
24. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials.
Mitsumoto H; Salgado ED; Negroski D; Hanson MR; Salanga VD; Wilber JF; Wilbourn AJ; Breuer AC; Leatherman J
Neurology; 1986 Feb; 36(2):152-9. PubMed ID: 3080695
[TBL] [Abstract][Full Text] [Related]
25. Clinical applications of thyrotrophin-releasing hormone.
Griffiths EC
Clin Sci (Lond); 1987 Nov; 73(5):449-57. PubMed ID: 3119272
[No Abstract] [Full Text] [Related]
26. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
[TBL] [Abstract][Full Text] [Related]
27. Further studies on the effects of a thyrotropin releasing hormone analogue on locomotor activity in the rat.
Clarke KA; Parker AJ
Neuropeptides; 1986; 8(2):99-109. PubMed ID: 3093913
[TBL] [Abstract][Full Text] [Related]
28. Effects of thyrotropin-releasing hormone in chronic schizophrenic patients.
Kobayashi K; Nakaoka K; Tsuji H; Shohmori T
Acta Med Okayama; 1980 Sep; 34(4):263-73. PubMed ID: 6452029
[TBL] [Abstract][Full Text] [Related]
29. TRH and diseases of the motor system.
Munsat TL; Lechan R; Taft JM; Jackson IM; Reichlin S
Ann N Y Acad Sci; 1989; 553():388-98. PubMed ID: 2497682
[No Abstract] [Full Text] [Related]
30. Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy.
Kato Z; Okuda M; Okumura Y; Arai T; Teramoto T; Nishimura M; Kaneko H; Kondo N
J Child Neurol; 2009 Aug; 24(8):1010-2. PubMed ID: 19666885
[TBL] [Abstract][Full Text] [Related]
31. Effects of thyrotropin-releasing hormone and its metabolites, Cyclo(His-Pro) and TRH-OH, on growth hormone and prolactin synthesis in primary cultured pituitary cells of the common carp, Cyprinus carpio.
Kagabu Y; Mishiba T; Okino T; Yanagisawa T
Gen Comp Endocrinol; 1998 Sep; 111(3):395-403. PubMed ID: 9707485
[TBL] [Abstract][Full Text] [Related]
32. High-dose TRH treatment of neuromuscular diseases: summary of mechanisms and critique of clinical studies. Summary of section IX.
Engel WK
Ann N Y Acad Sci; 1989; 553():462-72. PubMed ID: 2497686
[No Abstract] [Full Text] [Related]
33. Thyrotrophin-releasing hormone. New applications in the clinic.
Griffiths EC
Nature; 1986 Jul 17-23; 322(6076):212-3. PubMed ID: 3090448
[No Abstract] [Full Text] [Related]
34. Role of brainstem thyrotropin-releasing hormone-triggered sympathetic overactivation in cardiovascular mortality in type 2 diabetic Goto-Kakizaki rats.
Yang H; Nyby MD; Ao Y; Chen A; Adelson DW; Smutko V; Wijesuriya J; Go VL; Tuck ML
Hypertens Res; 2012 Feb; 35(2):157-65. PubMed ID: 21900943
[TBL] [Abstract][Full Text] [Related]
35. A double-blind trial of intravenous thyrotrophin-releasing hormone in the treatment of reactive depression.
Evans LE; Hunter P; Hall R; Johnston M; Roy VM
Br J Psychiatry; 1975 Sep; 127():227-30. PubMed ID: 810198
[TBL] [Abstract][Full Text] [Related]
36. Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone.
Imoto K; Saida K; Iwamura K; Saida T; Nishitani H
J Neurol Neurosurg Psychiatry; 1984 Dec; 47(12):1332-4. PubMed ID: 6439824
[TBL] [Abstract][Full Text] [Related]
37. Methodological considerations for clinical trials in motor neuron disease.
Shafer SQ; Olarte MR
Adv Neurol; 1982; 36():559-68. PubMed ID: 6758532
[No Abstract] [Full Text] [Related]
38. Effects of tartrate thyrotropin-releasing hormone treatment on serum thyrotropin, free triiodothyronine, free thyroxine and prolactin levels in patients with spinocerebellar degeneration.
Merola B; Colao A; Di Renzo G; Filla A; Campanella G; Lombardi G
Horm Res; 1992; 38(3-4):160-3. PubMed ID: 1306848
[TBL] [Abstract][Full Text] [Related]
39. Brainstem thyrotropin-releasing hormone regulates food intake through vagal-dependent cholinergic stimulation of ghrelin secretion.
Ao Y; Go VL; Toy N; Li T; Wang Y; Song MK; Reeve JR; Liu Y; Yang H
Endocrinology; 2006 Dec; 147(12):6004-10. PubMed ID: 16959836
[TBL] [Abstract][Full Text] [Related]
40. Controlled therapeutic trials in motor neuron disease: methodologic considerations.
Schoenberg BS
Adv Neurol; 1982; 36():547-53. PubMed ID: 6758530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
